Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedJan 29, 2026
DataAggregated Company Financials
Companies34
- 7D-3.9%
- 3M-5.6%
- 1Y-0.2%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 3.9%, driven by a pullback from PeptiDream of 7.6%. On the other hand Cuorips is actually up 5.8%. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to grow by 38% annually.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 30 Jan 2026 | JP¥1.1t | JP¥198.7b | -JP¥70,406,297,000.00 | 60.5x | -15.1x | 5.4x |
| Sun, 28 Dec 2025 | JP¥978.7b | JP¥198.7b | -JP¥70,727,387,000.00 | 52.7x | -13.8x | 4.9x |
| Tue, 25 Nov 2025 | JP¥1.1t | JP¥196.3b | -JP¥69,252,365,000.00 | 52.3x | -15.2x | 5.4x |
| Thu, 23 Oct 2025 | JP¥1.2t | JP¥197.7b | -JP¥65,502,224,000.00 | 65x | -17.6x | 5.8x |
| Sat, 20 Sep 2025 | JP¥1.2t | JP¥197.7b | -JP¥65,794,561,000.00 | 64.6x | -18.3x | 6.1x |
| Mon, 18 Aug 2025 | JP¥1.2t | JP¥193.5b | -JP¥68,256,278,000.00 | 119.2x | -17.6x | 6.2x |
| Wed, 16 Jul 2025 | JP¥1.1t | JP¥218.2b | -JP¥43,671,220,000.00 | 100.2x | -25x | 5x |
| Fri, 13 Jun 2025 | JP¥1.2t | JP¥216.3b | -JP¥42,942,705,000.00 | 91.4x | -28.7x | 5.7x |
| Sun, 11 May 2025 | JP¥1.1t | JP¥207.8b | -JP¥38,747,850,000.00 | 14.6x | -27.4x | 5.1x |
| Tue, 08 Apr 2025 | JP¥816.2b | JP¥207.7b | -JP¥39,165,298,000.00 | 12.6x | -20.8x | 3.9x |
| Thu, 06 Mar 2025 | JP¥987.8b | JP¥207.4b | -JP¥38,725,942,000.00 | 15.5x | -25.5x | 4.8x |
| Sat, 01 Feb 2025 | JP¥996.2b | JP¥207.3b | -JP¥13,514,452,000.00 | 20.7x | -73.7x | 4.8x |
| Mon, 30 Dec 2024 | JP¥1.1t | JP¥206.4b | -JP¥12,718,356,000.00 | 22.2x | -85.2x | 5.2x |
| Wed, 27 Nov 2024 | JP¥1.1t | JP¥207.2b | -JP¥11,247,446,000.00 | 21.5x | -96x | 5.2x |
| Fri, 25 Oct 2024 | JP¥1.1t | JP¥214.3b | -JP¥3,941,502,000.00 | 20.7x | -269.2x | 5x |
| Sun, 22 Sep 2024 | JP¥1.1t | JP¥214.3b | -JP¥2,078,229,000.00 | 20.2x | -542.4x | 5.3x |
| Tue, 20 Aug 2024 | JP¥1.0t | JP¥209.7b | -JP¥703,432,000.00 | 14.1x | -1466.2x | 4.9x |
| Thu, 18 Jul 2024 | JP¥1.1t | JP¥187.7b | -JP¥15,872,047,000.00 | 95.7x | -70.3x | 5.9x |
| Sat, 15 Jun 2024 | JP¥909.1b | JP¥193.8b | -JP¥15,007,284,000.00 | 99.3x | -60.6x | 4.7x |
| Mon, 13 May 2024 | JP¥796.4b | JP¥195.0b | -JP¥13,546,545,000.00 | 83.4x | -58.8x | 4.1x |
| Wed, 10 Apr 2024 | JP¥771.2b | JP¥194.2b | -JP¥15,457,837,000.00 | 65.8x | -49.9x | 4x |
| Fri, 08 Mar 2024 | JP¥804.9b | JP¥196.2b | -JP¥19,179,997,000.00 | 60.7x | -42x | 4.1x |
| Sun, 04 Feb 2024 | JP¥744.0b | JP¥222.4b | -JP¥12,442,827,000.00 | 17.5x | -59.8x | 3.3x |
| Tue, 02 Jan 2024 | JP¥814.6b | JP¥222.3b | -JP¥12,668,455,000.00 | 17.6x | -64.3x | 3.7x |
| Thu, 30 Nov 2023 | JP¥804.9b | JP¥221.9b | -JP¥12,426,487,000.00 | 16.9x | -64.8x | 3.6x |
| Sat, 28 Oct 2023 | JP¥718.5b | JP¥223.0b | -JP¥14,478,735,000.00 | 18x | -49.6x | 3.2x |
| Mon, 25 Sep 2023 | JP¥852.4b | JP¥223.0b | -JP¥14,518,735,000.00 | 27.5x | -58.7x | 3.8x |
| Wed, 23 Aug 2023 | JP¥875.6b | JP¥225.1b | -JP¥19,814,131,000.00 | 48.7x | -44.2x | 3.9x |
| Fri, 21 Jul 2023 | JP¥909.7b | JP¥223.0b | -JP¥19,998,669,000.00 | 47.9x | -45.5x | 4.1x |
| Sun, 18 Jun 2023 | JP¥966.4b | JP¥223.2b | -JP¥20,139,642,000.00 | 56.8x | -48x | 4.3x |
| Tue, 16 May 2023 | JP¥889.2b | JP¥222.5b | -JP¥19,168,670,000.00 | 19.3x | -46.4x | 4x |
| Thu, 13 Apr 2023 | JP¥936.7b | JP¥218.3b | -JP¥21,583,522,000.00 | 21.6x | -43.4x | 4.3x |
| Sat, 11 Mar 2023 | JP¥931.8b | JP¥218.1b | -JP¥18,469,580,000.00 | 21.1x | -50.5x | 4.3x |
| Mon, 06 Feb 2023 | JP¥944.4b | JP¥186.7b | -JP¥24,854,541,000.00 | 40x | -38x | 5.1x |
Price to Earnings Ratio
-38x
Current Industry PE
- Investors are optimistic on the Japanese Biotechnology industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 4.7x is lower than the industry's current PS ratio of 5.4x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 2.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Japanese Biotech compare with similar industries?
| JP Market | -1.33% | |
| Healthcare | -0.80% | |
| Biotech | -3.91% | |
| Biotech | -3.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4894 Cuorips | JP¥8.03k | 6.1% +JP¥3.8b | 82.9% | PS184x | |
| 7774 Japan Tissue Engineering | JP¥564.00 | 8.9% +JP¥1.9b | 13.7% | PS10x | |
| 4599 StemRIM | JP¥295.00 | 3.5% +JP¥626.8m | -8.7% | PB2.7x | |
| 7776 CellSeed | JP¥313.00 | 3.3% +JP¥355.6m | -18.7% | n/a | |
| 4575 CanBas | JP¥866.00 | 2.1% +JP¥344.0m | 3.1% | PB6.4x |
